SASKATOON, SK — February 9, 2026 — Leads & Copy —
ZYUS Life Sciences Corporation (TSXV: ZYUS) has filed an amended and restated offering document dated February 9, 2026, regarding its LIFE Offering. The amended document aligns with the “listed issuer financing exemption” under section 5A.2 of National Instrument 45-106 – Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935.
The offering, initially announced on January 12, 2026, has recommenced. The Amended and Restated Offering Document is accessible on SEDAR+ and the company’s website.
Prospective investors are advised to read the Amended and Restated Offering Document before making any investment decisions. Copies of the document can be obtained from Canaccord Genuity Corp., the lead agent and sole bookrunner for the LIFE Offering, via ECM@cgf.com.
ZYUS (TSXV: ZYUS) is focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. The company aims to secure intellectual property protection through scientific exploration and clinical research, while working toward regulatory approval of non-opioid-based pharmaceutical solutions.
ZYUS is a clinical stage life science company focussed on development and commercialization of non-opioid drug candidates for pain management.
For additional information, visit www.zyus.com or follow on X @ZYUSCorp.
Source: ZYUS Life Sciences Corporation
